Molecular Partners and Orano Med are expanding their collaboration on targeted cancer therapies utilizing the radioisotope lead-212 (212Pb). The new agreement includes four research programs, with each company holding marketing rights for two programs, and initial human studies for the ML0712 treatment are set to begin next year. Despite this expansion, there will be no immediate impact on the financial outlook for 2024, as Molecular Partners maintains its financing forecasts through 2027.